Business Standard

Indian pharma cos market revenue share up at 32% in Q2 FY13

Forex gains also contributed significantly to the bottom-line of many pharma companies

Press Trust of India  |  Mumbai 

The market continued its strong performance owing to a jump in revenue from the domestic market and new product launches.

Forex gains also contributed significantly to the bottom-line of many pharma companies for the quarter Q2 FY13.

"The domestic market contribution increased from 30% to 32% of revenues in Q2 of FY13. The domestic market continued its strong performance owing to the new product launches," Barclays Equity Research analyst Rohit Goel said in a report here.

Owing to strong high-teen growth levels in the domestic market, the share has gone up to 32% at Rs 15,394.9 crore in Q2 FY 12.

Domestic formulation growth at 18% year-on-year is slightly ahead of our expectations of mid-teen growth levels from India. This compares favorably with the 15% growth last year. Acute therapeutic segments grew by 11.7.2%, while chronic segment grew by 20.3%, the report said.

The outperformers in the Indian market were (35%), (28%) and (18%).

Operating margins continued to improve both sequentially (60bps) and on a y/y basis (280 bps), reaffirming Indian pharma's steady operating fundamentals. Glenmark, DRL and surprised on the upside while and Ranbaxy reported below expectations.

The gain in the US market share and forex aid 55% growth. The US formulations growth at 55% as against 33% in 2Q FY12 were driven by multiple major launches and were further accentuated by a 20% depreciation yoy, Goel said.

For 2Q FY13, forex gains have contributed significantly to support Cipla's and Ranbaxy's bottom-lines resulting in PAT-level individual outperformance despite overall sets of weak results. However, PAT for our coverage was 8% below our expectations because of the Rs 5.8 bn one-off provisioning taken by Sun Pharma, the report said.

Key one-offs that are unlikely to recur next year are revenues from Lexapro for Cipla, Lipodox for Sun Pharma and Lipitor to a smaller extent for Ranbaxy. Biochem acquisition (18% growth for without Biochem) also helped the strong growth trajectory.

RECOMMENDED FOR YOU

Indian pharma cos market revenue share up at 32% in Q2 FY13

Forex gains also contributed significantly to the bottom-line of many pharma companies

The Indian pharma market continued its strong performance owing to a jump in revenue from the domestic market and new product launches.

The market continued its strong performance owing to a jump in revenue from the domestic market and new product launches.

Forex gains also contributed significantly to the bottom-line of many pharma companies for the quarter Q2 FY13.

"The domestic market contribution increased from 30% to 32% of revenues in Q2 of FY13. The domestic market continued its strong performance owing to the new product launches," Barclays Equity Research analyst Rohit Goel said in a report here.

Owing to strong high-teen growth levels in the domestic market, the share has gone up to 32% at Rs 15,394.9 crore in Q2 FY 12.

Domestic formulation growth at 18% year-on-year is slightly ahead of our expectations of mid-teen growth levels from India. This compares favorably with the 15% growth last year. Acute therapeutic segments grew by 11.7.2%, while chronic segment grew by 20.3%, the report said.

The outperformers in the Indian market were (35%), (28%) and (18%).

Operating margins continued to improve both sequentially (60bps) and on a y/y basis (280 bps), reaffirming Indian pharma's steady operating fundamentals. Glenmark, DRL and surprised on the upside while and Ranbaxy reported below expectations.

The gain in the US market share and forex aid 55% growth. The US formulations growth at 55% as against 33% in 2Q FY12 were driven by multiple major launches and were further accentuated by a 20% depreciation yoy, Goel said.

For 2Q FY13, forex gains have contributed significantly to support Cipla's and Ranbaxy's bottom-lines resulting in PAT-level individual outperformance despite overall sets of weak results. However, PAT for our coverage was 8% below our expectations because of the Rs 5.8 bn one-off provisioning taken by Sun Pharma, the report said.

Key one-offs that are unlikely to recur next year are revenues from Lexapro for Cipla, Lipodox for Sun Pharma and Lipitor to a smaller extent for Ranbaxy. Biochem acquisition (18% growth for without Biochem) also helped the strong growth trajectory.

image
Business Standard
177 22

Indian pharma cos market revenue share up at 32% in Q2 FY13

Forex gains also contributed significantly to the bottom-line of many pharma companies

The market continued its strong performance owing to a jump in revenue from the domestic market and new product launches.

Forex gains also contributed significantly to the bottom-line of many pharma companies for the quarter Q2 FY13.

"The domestic market contribution increased from 30% to 32% of revenues in Q2 of FY13. The domestic market continued its strong performance owing to the new product launches," Barclays Equity Research analyst Rohit Goel said in a report here.

Owing to strong high-teen growth levels in the domestic market, the share has gone up to 32% at Rs 15,394.9 crore in Q2 FY 12.

Domestic formulation growth at 18% year-on-year is slightly ahead of our expectations of mid-teen growth levels from India. This compares favorably with the 15% growth last year. Acute therapeutic segments grew by 11.7.2%, while chronic segment grew by 20.3%, the report said.

The outperformers in the Indian market were (35%), (28%) and (18%).

Operating margins continued to improve both sequentially (60bps) and on a y/y basis (280 bps), reaffirming Indian pharma's steady operating fundamentals. Glenmark, DRL and surprised on the upside while and Ranbaxy reported below expectations.

The gain in the US market share and forex aid 55% growth. The US formulations growth at 55% as against 33% in 2Q FY12 were driven by multiple major launches and were further accentuated by a 20% depreciation yoy, Goel said.

For 2Q FY13, forex gains have contributed significantly to support Cipla's and Ranbaxy's bottom-lines resulting in PAT-level individual outperformance despite overall sets of weak results. However, PAT for our coverage was 8% below our expectations because of the Rs 5.8 bn one-off provisioning taken by Sun Pharma, the report said.

Key one-offs that are unlikely to recur next year are revenues from Lexapro for Cipla, Lipodox for Sun Pharma and Lipitor to a smaller extent for Ranbaxy. Biochem acquisition (18% growth for without Biochem) also helped the strong growth trajectory.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard